dc.contributor.author | Moreno Torres, Víctor | |
dc.contributor.author | Soriano, Vicente | |
dc.contributor.author | Calderón Parra, Jorge | |
dc.contributor.author | Martínez Urbistondo, María | |
dc.contributor.author | Treviño, Ana | |
dc.contributor.author | de San Vicente, Zayrho | |
dc.contributor.author | de Mendoza, Carmen | |
dc.contributor.author | Ruiz Irastorza, Guillermo | |
dc.date.accessioned | 2023-06-19T17:40:20Z | |
dc.date.available | 2023-06-19T17:40:20Z | |
dc.date.issued | 2023-06 | |
dc.identifier.citation | Autoimmunity Reviews 22(6) : (2023) // Article ID 103341 | es_ES |
dc.identifier.issn | 1873-0183 | |
dc.identifier.issn | 1568-9972 | |
dc.identifier.uri | http://hdl.handle.net/10810/61472 | |
dc.description.abstract | Introduction
SARS-CoV-2 infection and COVID-19 vaccines might have increased the incidence of giant-cell arteritis (GCA) and the risk of associated stroke in Spain.
Methods
Retrospective nation-wide observational analysis of all adults hospitalized with GCA in Spain during 5 years (Jan-2016 and Dec-2021). The incidence and proportion of admissions with or because of GCA and GCA-associated stroke were compared between pre-pandemic (2016–2019) and pandemic (2020 and 2021) years. Sensitivity analyses were conducted for the different COVID-19 waves and vaccine timing schedules.
Results
A total of 17,268 hospital admissions in patients diagnosed with GCA were identified. During 2020 there were 79.3 and 8.1 per 100,000 admissions of GCA and GCA-associated stroke, respectively. During 2021 these figures were 80.8 and 7.7 per 100,00 admissions, respectively. As comparison, yearly admissions due to GCA and GCA-associated stroke were 72.4 and 5.7 per 100,00, respectively, during the pre-pandemic period (p < 0.05). Coincident with the third wave of COVID-19 (and first vaccine dosing), the rate of GCA-associated stroke admissions increased significantly (from 6.7 to 12%; p < 0.001). Likewise, there was an increase in GCA-associated stroke (6.6% vs 4.1%, p = 0.016) coincident with the third dose vaccination (booster) in patients older than 70 at the end of 2021. In multivariate analysis, only patients admitted during the third COVID-19 wave (and first vaccine dosing) (OR = 1.89, 95% CI 1.22–2.93), and during the third vaccination dosing in patients older than 70 (booster) (OR = 1.66, CI 1.11–2.49), presented a higher GCA-associated stroke risk than the same months of previous years after adjustment by age, sex, classical cardiovascular risk factors and COVID-19 diagnosis.
Conclusions
The COVID-19 pandemic led to an increased incidence of GCA during 2020 and 2021. Moreover, the risk of associated stroke significantly risen accompanying times of COVID-19 vaccine dosing, hypothetically linked to an increased thrombotic risk of mRNA-SARS-CoV-2 vaccines. Hence, forthcoming vaccine policies and indications must weigh the risk of severe COVID-19 with the risk of flare or stroke in patients with GCA. | es_ES |
dc.description.sponsorship | Víctor Moreno-Torres received a grant from the Academia Medico-Quirúrgica Española. Guillermo Ruiz-Irastorza was supported by the Department of Education of the Basque Government, research grant IT 1512–22. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Elsevier | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.subject | giant cell arteritis | es_ES |
dc.subject | stroke | es_ES |
dc.subject | COVID-19 | es_ES |
dc.subject | SARS-CoV-2 vaccine | es_ES |
dc.title | Increased incidence of giant cell arteritis and associated stroke during the COVID-19 pandemic in Spain: A nation-wide population study | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.holder | © 2023 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). | es_ES |
dc.rights.holder | Atribución 3.0 España | * |
dc.relation.publisherversion | https://www.sciencedirect.com/science/article/pii/S1568997223000757 | es_ES |
dc.identifier.doi | 10.1016/j.autrev.2023.103341 | |
dc.departamentoes | Medicina | es_ES |
dc.departamentoeu | Medikuntza | es_ES |